Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

(RTTNews) - Sanofi (SNY), a French pharmaceutical and healthcare company, Friday announced that it is executing the second tranche of its share buyback program, to repurchase up to 2 billion euros ...

Sanofi (SNYNF – Research Report) received a Buy rating and price target from DZ BANK AG analyst Elmar Kraus today. The company’s shares closed yesterday at $108.00. According to TipRanks ...

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

Sanofi delivered robust Q4 2024 results with strong growth across key products and new launches, including Dupixent and Beyfortus. The company’s strategic focus on R&D, pipeline productivity ...

-Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.

The Food and Drug Administration has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility in Massachusetts where the company makes ...